News for Candel Therapeutics, Inc. (CADL)

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and

Candel Therapeutics, Inc.

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) ( CADL), a clinical stage biopharmaceutical company focused

**media[634772]**

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 311% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenove...

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) ( CADL), a clinical stage biopharmaceutical company focused

Candel Therapeutics (CADL) to participate in two major investor conferences in May and June 2025. Live webcasts available for investors on the company's

Candel Therapeutics (CADL) showcases promising results from its phase 1b trial, sparking investor interest. Analyst forecasts suggest a significant upsi

Key Highlights: Candel Therapeutics to present Phase 3 trial data for cancer immunotherapy at ASCO 2025 Analysts predict significant upside potential for

NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) ( CADL), a clinical stage biopharmaceutical company focus

NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmac...

Candel Therapeutics (CADL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

On March 19, 2025, Paul Tak, the CEO of Candel Therapeutics Inc (CADL), sold 26,172 shares of the company, according to a recent SEC Filing. Following this tran

NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) ( CADL), a clinical stage biopharmaceutical company focus

**media[571879]**

NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) ( CADL), a clinical stage biopharmaceutical company focus

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate

Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop due to market skepticism. Learn more on CADL stock here.